In an industry where a decision can impact billions of dollars and thousands of patients — and where each day of delayed launch can mean millions in lost revenue — many pharma companies remain trapped in slow and static decision-cycles. R&D teams, BD groups, and commercial functions tend to operate in silos. Spreadsheets, PowerPoints, and manual slides still drive critical decisions. The paradox? Although these functions are tightly intertwined in every asset and across the p

This simulation shows how Fast Track designation can shift both launch timing and value potential—turning uncertainty into actionable insight and helping teams make bold, data-driven investment decisions.

As tools like Eli Lilly’s TuneLab show, AI is starting to move beyond data hygiene—when fed with external context, embedded in dynamic workflows, and judged by its strategic impact, it can transform how we prioritize, plan, and win in drug development.

Happy Wednesday from the Captario Product team🎉 Frida, Johanna and I are on our way home after moderating a hands-on modeling & simulation workshop in Basel with a portfolio team here. It was a strong session—smart questions, productive debate, and several insights around how simulation helps us make better project and portfolio decisions under uncertainty. Also interesting to see how first-hand users interact with our tool!

To unlock AI’s full potential in portfolio decision-making, Pharma needs structured assumptions, dynamic project models, and simulation at scale—without them, even the smartest AI is flying blind.

This training model illustrates how control variables like fast track designation and Phase 2 design choices can transform a project simulation into a strategic tool for exploring trade-offs, timelines, and value.